Abstract
Recently, CRISPR-based techniques have significantly improved our ability to make desired changes and regulations in various genomes. Among them, targeted base editing is one of the most powerful techniques in making precise genomic editing. Base editing enabled the irreversible conversion of a specific single DNA base, from C to T or and from A to G, in desired genomic loci. This technique has important implications in the study of human genetic diseases, considering that many of them resulted from point mutations. More importantly, the high efficiency of these editing tools also provided great promise in clinical applications. In this review, we discuss the recent progress and challenges of base editing tools.
Keywords: CRISPR based techniques, genomes, targeted base editing, human genetic diseases, point mutations, base editing tools.
Graphical Abstract
Current Gene Therapy
Title:Recent Advances in CRISPR/Cas9 Directed Base Editing
Volume: 21 Issue: 4
Author(s): Nan Liu, Lifang Zhou, Junyan Qu and Shaohua Yao*
Affiliation:
- Laboratory of Biotherapy, National Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Renmin Nanlu 17, Chengdu 610041, Sichuan,China
Keywords: CRISPR based techniques, genomes, targeted base editing, human genetic diseases, point mutations, base editing tools.
Abstract: Recently, CRISPR-based techniques have significantly improved our ability to make desired changes and regulations in various genomes. Among them, targeted base editing is one of the most powerful techniques in making precise genomic editing. Base editing enabled the irreversible conversion of a specific single DNA base, from C to T or and from A to G, in desired genomic loci. This technique has important implications in the study of human genetic diseases, considering that many of them resulted from point mutations. More importantly, the high efficiency of these editing tools also provided great promise in clinical applications. In this review, we discuss the recent progress and challenges of base editing tools.
Export Options
About this article
Cite this article as:
Liu Nan , Zhou Lifang , Qu Junyan and Yao Shaohua *, Recent Advances in CRISPR/Cas9 Directed Base Editing, Current Gene Therapy 2021; 21 (4) . https://dx.doi.org/10.2174/1566523221666210322090638
DOI https://dx.doi.org/10.2174/1566523221666210322090638 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial
Current Pharmaceutical Design Development of Gel-Core Solid Lipid Nanoparticles as Drug Delivery Systems for Hydrophilic Molecules
Current Nanoscience Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients
Current Cancer Drug Targets Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Dietary Antioxidants: Immunity and Host Defense
Current Topics in Medicinal Chemistry Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products
Recent Patents on Food, Nutrition & Agriculture Biocompatibility and Solubility of Fe3O4-BSA Conjugates with Human Blood
Current Nanoscience Editorial (Thematic Issue: The Biological Approach to Advanced Cancer: Are We in the Middle of the Road?)
Current Drug Targets Lipoamino Acid Prodrugs of Paclitaxel: Synthesis and Cytotoxicity Evaluation on Human Anaplastic Thyroid Carcinoma Cells
Current Cancer Drug Targets Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
Current Pharmaceutical Design